<DOC>
	<DOCNO>NCT00758264</DOCNO>
	<brief_summary>The purpose study demonstrate , 12-23 month old subject , non-inferiority meningococcal vaccine GSK134612 pneumococcal vaccine GSK1024850A co-administered , compare vaccine administer individually .</brief_summary>
	<brief_title>Co-administration Meningococcal Vaccine GSK134612 Pneumococcal Vaccine GSK1024850A v Individual Administration</brief_title>
	<detailed_description>Multi-center study 3 parallel group . One group receive 2 vaccine injection visit ( pneumococcal+ meningococcal ) , one group receive pneumococcal vaccine follow one month later meningococcal vaccine , last group receive meningococcal vaccine follow one month later pneumococcal vaccine . All subject one blood sample take vaccination one blood sample take one month vaccination ( i.e . first group 2 blood sample take , two group 3 blood sample take )</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol . A male female , include , 12 23 month age time first booster vaccination , previously participate study 109661 conduct Mexico study 109861 conduct Taiwan receive 3 dos GSK1024850A vaccine . Written inform consent obtain parent guardian subject . Healthy subject establish medical history clinical examination enter study . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine ( ) , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/ administration vaccine foreseen study protocol within 30 day first dose vaccine ( ) 30 day last dose vaccine ( ) . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Previous vaccination meningococcal vaccine . Previous administration fourth dose pneumococcal vaccine Previous vaccination tetanus toxoid within last month ( include also tetanus toxoid give part HibTT conjugate vaccine ) . History meningococcal pneumococcal invasive disease . History reaction allergic disease likely exacerbate component vaccine . Hypersensitivity reaction due previous vaccination GSK1024850A vaccine . History seizure ( criterion apply subject single , uncomplicated febrile convulsion past ) progressive neurological disease . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection , base medical history physical examination ( laboratory testing require ) . A family history congenital hereditary immunodeficiency , unless child previously document , laboratory testing , normal immune function . Major congenital defect serious chronic illness . Acute disease time enrolment . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>23 Months</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Safety</keyword>
	<keyword>Routine infancy vaccination</keyword>
	<keyword>Meningococcal vaccine</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Pneumococcal vaccine</keyword>
</DOC>